Zacks: Brokerages Expect Presbia (LENS) to Announce -$0.21 Earnings Per Share

Equities research analysts forecast that Presbia (NASDAQ:LENS) will post ($0.21) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Presbia’s earnings. Presbia posted earnings of ($0.32) per share in the same quarter last year, which indicates a positive year over year growth rate of 34.4%. The firm is scheduled to report its next quarterly earnings report on Friday, May 11th.

On average, analysts expect that Presbia will report full-year earnings of ($0.67) per share for the current financial year. Zacks’ earnings per share calculations are a mean average based on a survey of analysts that cover Presbia.

Separately, HC Wainwright reissued a “buy” rating and set a $7.00 target price on shares of Presbia in a research report on Wednesday, December 20th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $9.67.



LENS stock opened at $2.63 on Friday. Presbia has a twelve month low of $1.86 and a twelve month high of $7.14. The stock has a market cap of $44.19, a P/E ratio of -2.23 and a beta of 0.10.

COPYRIGHT VIOLATION WARNING: “Zacks: Brokerages Expect Presbia (LENS) to Announce -$0.21 Earnings Per Share” was reported by Dakota Financial News and is the property of of Dakota Financial News. If you are reading this news story on another domain, it was illegally copied and republished in violation of United States and international trademark & copyright law. The correct version of this news story can be read at https://dakotafinancialnews.com/2018/04/13/zacks-brokerages-expect-presbia-lens-to-announce-0-21-earnings-per-share.html.

About Presbia

Presbia PLC, an ophthalmic device company, develops and markets optical lens implants for treating presbyopia. The company provides the refractive lens for patient surgeries, as well as accessories for procedures. It primarily operates in South Korea, Australia, the Netherlands, Ireland, and Canada. The company was founded in 2014 and is headquartered in Dublin, Ireland.

Get a free copy of the Zacks research report on Presbia (LENS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Presbia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Presbia and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply